文献速递外周动脉疾病

糖尿病对慢性肢体威胁性缺血血运重建术后结局的影响:系统评价与荟萃分析

Impact of Diabetes on Outcomes after Lower Limb Revascularization in Patients with Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-Analysis.
PubMed 文献 · Ann Vasc Surg · 2026-07-14

该系统评价与荟萃分析纳入10项观察性研究共50242例患者,评估糖尿病对CLTI血运重建术后全因死亡和大截肢的影响。汇总分析显示糖尿病与全因死亡(HR 1.23;95%CI 1.04-1.46)和大截肢(HR 1.43;95%CI 1.23-1.66)风险显著升高相关。按随访时间亚组分析,大截肢风险在长期随访(≥3年)时显著增加(HR 1.56;95%CI 1.32-1.85;P<0.001)。

要点

  • 糖尿病与CLTI血运重建术后全因死亡及大截肢风险升高相关
  • 大截肢风险随随访时间延长而累积,≥3年时显著增加
  • 死亡风险在各时间亚组中均未达统计学显著

核心结论

  • 糖尿病可能与CLTI血运重建术后大截肢风险的时间依赖性累积相关,随访超过3年后效应逐渐显现。
  • 死亡差异在任何时间亚组中均不显著。
  • 研究结果强调糖尿病患者CLTI需持续肢体监测并整合血运重建与心脏代谢管理策略。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE、Embase和Cochrane Library的观察性研究。
  • 纳入比较糖尿病与非糖尿病CLTI患者下肢血运重建结局的研究,最低随访1年。
  • 共纳入10项观察性研究,50242例患者。
  • 主要结局为全因死亡和大截肢,以风险比(HR)及95%置信区间(CI)报告。
  • 按随访时长行亚组分析(中期1-2年;长期≥3年),并行荟萃回归探索异质性来源。

主要发现

  • 汇总分析中,糖尿病与全因死亡风险显著升高相关(HR 1.23;95%CI 1.04-1.46;I2=87.6%)。
  • 糖尿病与大截肢风险显著升高相关(HR 1.43;95%CI 1.23-1.66;I2=62.3%)。
  • 中期随访死亡风险无显著差异(HR 1.36;95%CI 0.97-1.90;P=0.075),长期随访亦无显著差异(HR 1.18;95%CI 0.95-1.46;P=0.10)。
  • 中期随访大截肢风险无显著差异(HR 1.24;95%CI 0.97-1.59;P=0.08),长期随访显著增加(HR 1.56;95%CI 1.32-1.85;P<0.001)。
  • 荟萃回归显示随访时长是大截肢风险的唯一显著调节因素(β=0.0214;P=0.024;R2=35.65%)。

临床怎么用

  • 对糖尿病合并CLTI血运重建术后患者,应坚持长期肢体监测,尤其关注3年以上大截肢风险累积。
  • 治疗策略需整合血运重建与心脏代谢综合管理,而非仅关注血管开通。

局限性

  • 所有分析均存在显著异质性。
  • 纳入研究均为观察性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diabetes mellitus significantly increases the risk of chronic limb-threatening ischemia (CLTI), leading to more severe arterial disease and worse outcomes. Its independent role in mortality and major amputation post-revascularization is still unclear, especially across various follow-up periods. This systematic review and meta-analysis aimed to assess the impact of diabetes on all-cause mortality and major lower-extremity amputation in CLTI patients undergoing revascularization. METHODS: A systematic search was conducted in MEDLINE, Embase, and Cochrane Library for observational studies comparing outcomes between diabetic and nondiabetic patients with CLTI undergoing lower-extremity revascularization, with a minimum follow-up of one year. The primary outcomes were all-cause mortality and major amputation, reported as hazard ratios (HRs) with 95% confidence intervals (CIs). Subgroup analyses were stratified by follow-up duration (mid-term: 1-2 years; long-term: ≥3 years). Meta-regression was performed to investigate sources of heterogeneity. Analyses were conducted in R (version 4.4.0) using the "meta" package. RESULTS: Ten observational studies with 50,242 patients were included. In the pooled analysis, diabetes was associated with significantly higher risks of all-cause mortality (HR 1.23; 95% CI 1.04-1.46; I2 = 87.6%) and major amputation (HR 1.43; 95% CI 1.23-1.66; I2 = 62.3%). In temporal subgroup analyses, no significant differences in mortality were observed at mid-term (HR 1.36; 95% CI 0.97-1.90; P = 0.075) or long-term follow-up (HR 1.18; 95% CI 0.95-1.46; P = 0.10). For amputation, the risk was nonsignificant in the mid-term (HR 1.24; 95% CI 0.97-1.59; P = 0.08) but significantly increased in the long-term (HR 1.56; 95% CI 1.32-1.85; P < 0.001). Meta-regression identified follow-up duration as the only significant moderator of amputation risk (β = 0.0214; P = 0.024; R2 = 35.65%). Substantial heterogeneity persisted across all analyses. CONCLUSION: Diabetes mellitus may be associated with a time-dependent accumulation of major amputation risk following revascularization for CLTI, with a progressive effect emerging beyond 3 years of follow-up. Mortality differences were not significant at any temporal subgroup. These findings underscore the need for sustained limb surveillance in diabetic patients with CLTI and highlight the importance of integrated revascularization and cardiometabolic management strategies.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Estevam R, Rocha G, Morais L, et al. Impact of Diabetes on Outcomes after Lower Limb Revascularization in Patients with Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-Analysis. Ann Vasc Surg. 2026. PMID: 42448033. doi:10.1016/j.avsg.2026.06.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。